15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 14 firms covering Protagonist Therapeutics Inc, 13 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $69.00 to $151.00 (about 2.2x), a sign of real disagreement on valuation. The average target of $113.50 sits 17% below the current $136.76. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.36 next quarter toward $-0.19 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS14 ratings
Strong Buy
Strong Buy00%
Buy1393%
Hold17%
Sell00%
Strong Sell00%
Based on 14 analysts giving stock ratings to Protagonist Therapeutics Inc.
As of Jul, 13 of 14 firms rate PTGX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PTGX EPS & revenue forecast
EPS · NEXT QUARTER
$2.36
Range $-0.23 – $3.71 · 9 analysts · -481% YoY
Next period, 9 analysts expect Protagonist Therapeutics Inc to earn $2.36 a share (range $-0.23 – $3.71), versus $-0.62 a year earlier. Full-year consensus is $4.47, growing to $-0.19 the year after.
REVENUE · NEXT QUARTER
$214.9M
Range $80.4M – $287.0M · 9 analysts · +4461% YoY
Revenue is expected to reach $214.9M (range $80.4M – $287.0M), +4460.7% year-over-year. Full-year consensus is $529.8M, rising to $184.6M next year.
Top analysts covering Protagonist Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PTGX.
#1
Jonathan Wolleben
JMP Securities · Rank #38
Buy
$137.00+0.2% to target
Overall win rate
44%
+ Follow
#2
Douglas Tsao
HC Wainwright & Co. · Rank #212
Buy
$117.00-14.5% to target
Overall win rate
35%
+ Follow
#3
Etzer Darout
Barclays
Buy
$151.00+10.4% to target
Coverage
—
+ Follow
#4
SD
Srikripa Devarakonda
Truist Securities
Buy
$145.00+6.0% to target
Coverage
—
+ Follow
#5
Geoff Meacham
Citigroup
Buy
$130.00-4.9% to target
Coverage
—
+ Follow
PTGX stock forecast FAQ
What is PTGX's average 12-month price target?+
The 14 analysts with a live target average $113.50 for Protagonist Therapeutics Inc over the next 12 months, ranging from a $151.00 high to a $69.00 low.
Is PTGX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 14 analyst ratings, 13 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PTGX?+
The Street-high target is $151.00 (Barclays), and the Street-low is $69.00 (JMP Securities). The average of all 14 active targets is $113.50.
How many Wall Street analysts cover PTGX?+
14 analysts have an active rating on Protagonist Therapeutics Inc, and 14 firms carry a live 12-month price target.
Who is the most accurate analyst covering PTGX?+
Among analysts who currently cover PTGX, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #38). Their current call is Buy with a $137.00 target.
What is Protagonist Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $2.36 per share (range $-0.23 – $3.71) across 9 analysts. Full-year EPS is projected at $4.47, rising to $-0.19 the following year.
How much revenue is Protagonist Therapeutics Inc expected to report next quarter?+
Consensus revenue is $214.9M (range $80.4M – $287.0M). Full-year revenue is projected at $529.8M, growing to $184.6M next year.
Have analysts been upgrading or downgrading PTGX lately?+
As of Jul, 13 of 14 firms rate PTGX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PTGX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
